Veraxa Biotech Holding AG (VRXA) Cash & Equivalents (2024 - 2025)

Veraxa Biotech Holding AG (VRXA) has reported Cash & Equivalents for 2 consecutive years, with $126368.1 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 97.94% year-over-year to $126368.1; the trailing twelve-month figure through Dec 2025 stood at $126368.1 (down 97.94% YoY), and the FY2025 full-year result was $126368.1, down 97.94% from the prior year.
• Cash & Equivalents retreated to $126368.1 in Q4 2025 per VRXA's latest filing, from $6.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $6.1 million in Q4 2024 to a low of $126368.1 in Q4 2025.